Neuroleptic malignant syndrome associated with the use of risperidone, an atypical antipsychotic agent

1 July 1994

journal article
case report
Published by Wiley in Human Psychopharmacology: Clinical and Experimental

Vol. 9 (4) , 303-305
https://doi.org/10.1002/hup.470090410

Abstract

Neuroleptic malignant syndrome (NMS) is a rare and sometimes fatal adverse reaction to neuroleptic drugs. Atypical antipsychotic agents, such as risperidone, are thought to be less likely to cause NMS because of their pharmacological profile. This is a case report of NMS associated with risperidone treatment.

Keywords

This publication has 10 references indexed in Scilit:

Neuroleptic Malignant Syndrome: Diagnostic Issues
Psychiatric Annals, 1991
Fluoxetine and Side Effects
Archives of General Psychiatry, 1990
Therapeutic effect and safety of increasing doses of risperidone (R 64766) in psychotic patients
Psychopharmacology, 1989
NEUROLEPTIC MALIGNANT SYNDROME AFTER CLOZAPINE PLUS CARBAMAZEPINE
The Lancet, 1988
Spectrum Concept of Neuroleptic Malignant Syndrome
The British Journal of Psychiatry, 1988
Neuroleptic malignant syndrome: review and analysis of 115 cases
Biological Psychiatry, 1987
The Neuroleptic Malignant Syndrome, So-called
The British Journal of Psychiatry, 1987
The Positive and Negative Syndrome Scale (PANSS) for Schizophrenia
Schizophrenia Bulletin, 1987
Neuroleptic malignant syndrome
American Journal of Psychiatry, 1985
Neuroleptic malignant syndrome
Neurology, 1981